News About: Pharm. Industry
Government to seek for long-term plans to improve innovative pharmaceutical company certificate
The government will seek for long-term plans towards effectiveness from the innovative pharmaceutical company certificate.
The Korea Health Industry Development Institute had a notice of tender for the ‘Studies for ...
6 more Korean pharmaceutical companies with sales higher than KRW 100 billion
Last year, 58 Korean pharmaceutical companies reportedly had more than KRW 100 billion annual sales.
Moreover, Korean pharmaceutical companies had an increase on average in sales, but the sales gap between the rich a...
Biopharmaceutical companies using advertising agencies for 67 brands
While Korean biopharmaceutical companies rely ‘entirely’ on advertising agencies, multinational pharmaceutical companies were mostly asking them to ‘buy and plan marketing content’ from them.
Moreover, pharmaceutical...
SK Chemicals signs joint sales agreement of ‘Forsteo’ with Lilly Korea
SK Chemicals announced the company signed a joint sales agreement of ‘Forsteo Inj(generic name: teriparatide),’ a medicine stimulating bone formation, with Lilly Korea on the 19th.
Forsteo is the world’s first medici...
2 of 5 unlisted pharmas struggling with SG&A/sales ratio higher than 40%
2 of 5 unlisted pharmaceutical companies reportedly have the ratio of SG&A(selling, general and administrative) expenses to sales higher than 40%.
Yakup Shinmoon(www.yakup.com) analyzed 2017 audit reports that 82 unl...
Small and medium pharmas with weakened profitability and high reliability on loans
Small and medium pharmaceutical companies were reportedly weakened in profitability and were relying more on loans.
Yakup Shinmoon(www.yakup.com) analyzed times interest earned(TIE) reported by 81 unlisted pharmaceut...
Accumulated assignments to resolve when getting clinical studies done in China
For difficulties to conduct clinical studies in China, people picked: devaluation of clinical studies at hospitals, financial opacity and immaturity of the IRB review process.
At the KOREA PHARM & BIO 2018 on the 18t...
How come health insurance benefits cut by illegal rebates never recover?
It was argued that health insurance benefits that are cut off due to illegal rebate should recover in a certain time. It was criticized it was too hard for pharmaceutical companies because there is no regulations to r...
Ilyang Pharmaceutical’s Parkinson’s disease drug candidate ‘Supect’ stated in international SCI journal
Ilyang Pharmaceutical(CEO Dong-Yeon Kim) announced ‘Supect(generic name: radotinib),’ the 18th Korean new drug candidate for the treatment of Parkinson’s disease, was approved to be published in ‘Human Molecular Genet...
High expectations on special plans for ‘desk for illegal rebates,’ CSOs
The industry might find new approaches to manage CSOs(contract sales organizations)
The reason why the industry has raised interests in CSOs again is because CSO is an official agenda at the ‘Ethical Management Works...
